Home / Business and Economy / GSK Surges Ahead: Vaccines and Specialty Meds Fuel Impressive Q3 Growth
GSK Surges Ahead: Vaccines and Specialty Meds Fuel Impressive Q3 Growth
13 Nov
Summary
- GSK reports 7% sales growth in Q3 2025, driven by vaccines, specialty medicines
- Core operating profit and EPS rise 11% and 14% respectively
- Company upgrades 2025 guidance, expects 9-11% profit and 10-12% EPS growth
As of November 13, 2025, global healthcare and biopharmaceutical company GSK plc (NYSE:GSK) has reported impressive financial results for the third quarter of the year. The company's total sales for the quarter reached £8.5 billion, up 7% on an actual exchange rate (AER) basis and 8% on a constant exchange rate (CER) basis. This growth was primarily driven by strong performance in the company's Vaccines, Specialty Medicines, and General Medicines divisions.
Sales in the Specialty Medicines segment rose 16% to £3.4 billion, while Respiratory, Immunology & Inflammation sales grew 15% to £1.0 billion. Oncology and HIV sales also experienced significant increases of 39% and 12%, respectively. Vaccine sales in Q3 2025 increased 2% to £2.7 billion.
The robust top-line growth translated to strong profitability, with core operating profit rising 11% and core earnings per share (EPS) experiencing a 14% expansion. This performance reflects the growth in Specialty Medicines and Vaccines, higher royalty income, and increased investment in R&D portfolio progression in Oncology and Vaccines.
Encouraged by these results, GSK has upgraded its 2025 guidance. The company now expects core EPS growth of between 10% to 12%, up from the previous range of 6% to 8%. Similarly, core operating profit growth is projected to be in the 9% to 11% range, compared to the earlier 6% to 8% guidance.
